Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 79.1%

Neg 0% Neu 0% Pos 79.1%

Goldman Sachs analyst Salveen Richter maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $35 to $40.